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Abstract: The noble gas helium (He) induces cardioprotection in vivo through unknown molecular
mechanisms. He can interact with and modify cellular membranes. Caveolae are cholesterol and
sphingolipid-enriched invaginations of the plasma-membrane-containing caveolin (Cav) proteins
that are critical in protection of the heart. Mice (C57BL/6J) inhaled either He gas or adjusted
room air. Functional measurements were performed in the isolated Langendorff perfused heart
at 24 h post He inhalation. Electron paramagnetic resonance spectrometry (EPR) of samples was
carried out at 24 h post He inhalation. Immunoblotting was used to detect Cav-1/3 expression
in whole-heart tissue, exosomes isolated from platelet free plasma (PFP) and membrane fractions.
Additionally, transmission electron microscopy analysis of cardiac tissue and serum function and
metabolomic analysis were performed. In contrast to cardioprotection observed in in vivo models,
the isolated Langendorff perfused heart revealed no protection after He inhalation. However, levels of
Cav-1/3 were reduced 24 h after He inhalation in whole-heart tissue, and Cav-3 was increased in
exosomes from PFP. Addition of serum to muscle cells in culture or naïve ventricular tissue increased
mitochondrial metabolism without increasing reactive oxygen species generation. Primary and lipid
metabolites determined potential changes in ceramide by He exposure. In addition to direct effects
on myocardium, He likely induces the release of secreted membrane factors enriched in caveolae.
Our results suggest a critical role for such circulating factors in He-induced organ protection.
Keywords: noble gas; helium; cardioprotection; caveolins; membranes; conditioning
1. Introduction
Helium (He), a noble gas without anesthetic properties, induces profound protection against
ischemia–reperfusion (I-R) injury in different organs of animals [1,2] and humans [3]. In both animals
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and humans, He preconditioning has shown to be cardioprotective in an early (directly to several
minutes after He exposure) and late phase (20–24 h after He exposure) [3,4]. Although organ protection
by He is observed in cell and animal models, and also in humans, data are sparse regarding a possible
molecular mechanism of this cardiac protection.
Previous work on ischemic and pharmacological preconditioning stimuli has shown that the
sarcolemma localizes a variety of receptors whose stimulation leads to the triggering of cardiac
protection. This trigger leads to activation of a number of mediators localized in the cytoplasm, such
as tyrosine kinases (Src), prosurvival kinases (including phosphatidylinositol-3-kinase (PI3K)), protein
kinase B (Akt) and glycogen synthase kinase 3b (GSK3b) [5]. Also, protein kinases such as protein
kinase G (PKG), protein kinase A (PKA) and protein kinase C (PKC) isoforms, as well as nitric oxide
synthase (NOS) and mitogen activated protein kinases (MAPK), have been shown to be crucially
involved in preconditioning of the heart [5]. To date, it is accepted that all these mediators converge
upon the mitochondria to modulate functions (including permeability transition pore (mPTP) function),
energetics, reactive oxygen species (ROS) generation and ultimately provide cardiac protection [5].
Work from our group and others link He-induced cardiac protection to mitochondrial signaling
pathways [6–9]. Moreover, emerging evidence shows that rapid coupling of the plasma membrane to
mitochondria via caveolins simultaneously activates numerous parallel pathways important in cardiac
protection [10–12]. Caveolae are cholesterol- and sphingolipid-enriched invaginations of the plasma
membrane and are a subset of lipid rafts [13]. Caveolins, the structural proteins essential for caveolae
formation, are present in three isoforms [14,15]: Caveolin-1 and -2 (Cav-1 and -2) are expressed in
multiple cell types, while caveolin-3 (Cav-3) is found primarily in striated (skeletal and cardiac) muscle
and certain smooth muscle cells [16]. Most importantly, caveolins have been shown to be critically
involved in ischemic as well as volatile anesthetic-induced conditioning [17–20], and have been detected
in mitochondria [10,21], where they modulate mitochondrial function [10,22,23]. It was previously
shown that Cav-1 and Cav-3 levels are influenced by He pre and post conditioning in two different rat
models [24,25]. Moreover, recently we were able to show that He preserves endothelial function by
inducing the secretion of Cav-1 to the supernatant of human endothelial cells, with subsequent effects
on endothelial permeability [26]. We hypothesized that the protective effect of helium is dependent
on membrane modulation, and sought to determine the in vivo implication of He on the heart with a
specific emphasis on membrane caveolin modulation in this study.
2. Results
2.1. Cardioprotection Ex Vivo
Numerous studies in vivo have shown a protective effect of He against cardiac
ischemia–reperfusion injury [4,6,27], but no studies have explored if this is a direct effect on the heart.
Cardiac function was evaluated 24 h after He or control (Ctrl) gas exposure using the Langendorff
perfused heart. In this isolated heart preparation, all circulating factors and neuro-hormonal
regulation of cardiac function are eliminated. Interestingly, no significant protective effect against
ischemia-reperfusion injury was observed in the hearts from He-treated mice (Figure 1A–D) in this
system. Therefore, He exposure does not result in cardiac protection from ischemia–reperfusion injury
in the Langendorff perfused heart 24 h after exposure.
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Figure  1.  Langendorff  perfused  hearts. Helium  did  not  result  in  increased  recovery  after  global 
ischemia  in  the  Langendorff  perfused  isolated  heart  24  h  after  exposure.  Cardiac  function  was 
measured as (A) left ventricular developed pressure (LVDP), (B) left ventricular end diastolic pressure 










exposure  (Figure  2).  However,  when  we  assessed  Cav‐1  and  Cav‐3  protein  levels  in  these 
compartments at 24 h post He inhalation, we observed a loss of Cav‐1 and ‐3 in whole‐heart lysates 
and membrane  fractions  in  the He‐exposed mice  (Figure 3A,B, units are average  light  intensity), 
whole heart (Cav‐1: 0.4 ± 0.3; Cav‐3: 0.7 ± 0.3) compared with the time‐matched control (Cav‐1: 1.7 ± 
0.7; Cav‐3: 1.3 ± 0.4) (both p < 0.05), and membrane fraction (Cav‐1: 1.0 ± 0.2; Cav‐3: 0.5 ± 0.2) versus 







Figure 1. Langendorff perfused hearts. eliu did not result in increased recovery after global
ischemia in the Langendorff perfused isolated heart 24 h after exposure. Cardiac function was measured
as (A) left ventricular developed pressure (LVDP), (B) left ventricular end diastolic pressure (LVEDP),
(C) contractility (dP/dtmax) and (D) lusitropy (dP/dtmin). Data are presented as mean ± standard
deviation (SD) (n = 7 for helium, n = 9 for control) and results were considered significant when p < 0.05.
2.2. Circulating Protective Factors
G ven the unexpected loss f He-induced protection in the isolated perfused heart, we hypothesized
that He might induce protection through release of various circulating factors related to caveolin that
have been shown to be protective in anaesthetic-induced cardiac protection [11,20,28]. We initially
performed western blot analysis of the whole-heart tissue and membrane and cytosolic fractions of
heart tissue, as well as exosome isolation from platelet free plasma (PFP). We observed no changes in
Cav-1 or -3 in whole-heart lysates and membrane tissue fractions at 30 min post He exposure (Figure 2).
However, when we assessed Cav-1 and Cav-3 protein levels in these compartments at 24 h post He
inhalation, we observed a loss of Cav-1 and -3 in whole-heart lysates and membrane fractions in the
He-exposed mice (Figure 3A,B, units are average light intensity), whole heart (Cav-1: 0.4 ± 0.3; Cav-3:
0.7 ± 0.3) compared with the time-matched control (Cav-1: 1.7 ± 0.7; Cav-3: 1.3 ± 0.4) (both p < 0.05),
and membrane fraction (Cav-1: 1.0 ± 0.2; Cav-3: 0.5 ± 0.2) versus control (Cav-1: 2.2 ± 1.1; Cav-3:
1.4 ± 0.4) (both p < 0.05); no changes in cytosolic fraction were observed. Accordingly, exosomes
isolated from PFP showed significantly increased Cav-3 expression and a tendency of increased Cav-1
in the He-treated mice (Figure 3C) (Cav-1: 13.5 ± 7.6; Cav-3: 12.7 ± 4.1, Cav-3 p<0.05) versus the
time-matched control (Cav-1: 11.6 ± 2.1; Cav-3: 1.6 ± 1.4). These data suggest that He exposure
produces caveolar-membrane-specific modifications leading to the release of circulating Cav-3-enriched
factors that may potentiate the protective effects of He.
















Figure 2. Cav-1 and Cav-3 levels in cardiac tissue 30 min post helium exposure. (A) Cav-1 and Cav-3
levels measured by western blot analysis in whole-heart tissue of mice as was the internal standard
GAPDH, n = 8. (B) Cav-1 and Cav-3 levels measured by western blot analysis in membrane fractions of
mice, as was the internal standard Na+K+-ATPase, n = 4. Data are shown as mean ± SD. No significant
differences were observed in the different tissues 30 min post He exposure, suggesting that He does not




Figure 2. Cav‐1 and Cav‐3 l vels in cardiac tissue 30 min  t  li  exposure. (A) Cav‐1 and Cav‐3 
levels measured by western blot  naly is in whole‐heart ti   f  ice as was the internal standard 
GAPDH, n = 8. (B) Cav‐1 and Cav‐3 l vels measured by western blot analysis in  e   tions 










Figure 3. Cav-1 and Cav-3 levels in different tissues at the 24-h time point. (A) Cav-1 and Cav-3 levels
were significantly lower in He whole-heart tissue of helium-treated mice, measured by western blot
analysis. (B) Cav-1 and Cav-3 levels were significantly lower in membrane fractions of He-treated
mice, measured by western blot analy is, n = 4. (C) Cav-3 lev ls wer significantly higher in exosomes
isolated from PFP of H - reated mice, measured by west rn blot analys s = 4. Data are shown as
mean ± SD, p < 0.05 was consid red statistically significant. As C v-1 and Cav-3 levels are lower in
whole-heart lysate and membrane fractions but higher in exosomes of PFP at the same time point,
these data suggest a secretion of Cav-1 and Cav-3 from cellular membranes located in the heart into
the bloodstream.
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2.3. Cav-1 and -3 Expression
Given the loss of caveolins from heart tissue and the increase in serum, we determined if the loss
of caveolin in the heart was related to changes in mRNA. Cav-1 and -3 qRT-PCR was performed 24
h after He inhalation. Neither Cav-1 nor Cav-3 mRNA levels changed at this time point (Figure 4).
These data suggest that the decreased levels of Cav-1 and -3 at the 24-h time point are caused rather by
altered protein translocation/secretion than by transcriptional regulation.












Figure  4.  Cav‐1  and  Cav‐3  mRNA  levels.  Histogram  shows  the  results  of  the  real‐time  PCR 
experiments of mice whole‐heart tissue. Upper panel is Cav‐1 over GAPDH. and lower panel is Cav‐





To  further  determine  the  impact  of  He  exposure  on  cardiac  ultrastructure,  we  performed 
transmission electron microscopy analysis of heart tissue and characterization of membrane fluidity 
and  PFP.  The  analysis  of  images  with  11,000×  magnification  on  the  left  ventricle  showed  no 
differences in the number of caveolae/μm in sarcolemma (Figure 5A,B) at either 30 min or 24 h post 










significant  changes  after  He  administration.  However,  a  trend  towards  decreased  rigidity  was 
observed in whole‐heart tissue and a trend (p = 0.099) towards increased rigidity was measured in 
Figure 4. Cav-1 and Cav-3 mRNA levels. Histogram shows the results of the real-time PCR experiments
of mice whole-heart tissue. Upper panel is Cav-1 over GAPDH. and lower panel is Cav-3 over
GAPDH (n = 5 for control and n = 6 for helium). No significant changes were observed, suggesting
that the increase of Cav-3 in exosomes from PFP at this time point is not due to higher levels of
Cav-3 gene expression but through a different mechanism, such as the direct release of Cav-3 from
plasma membranes.
2.4. Cardiac Ultrastructure, Cholesterol Quantity and Blood Plasma Fluidity
To further determine the impact of He exposure on cardiac ultrastructure, we performed
transmission lectron icroscopy analysis of heart tissue a d char teriz tion of membrane fluidity
and PFP. The analysis of images with 11,000×magnification on t e left ventricle showed no differences
i the number of c veolae/µm in sarcolemma (Figure 5A,B) at either 30 min or 24 h post He exposure.
Furth r ultras ructural analysis focusing on the siz , shape and organization of subsarcolemmal and
intermy fibrillar mitochondria of cardiomyocytes showed no obvious chang s. However, whe the
whole-heart lysate was assessed for cholesterol (a majo structural component of membrane and
caveola ), a significant decrease was observed 24 h after He inhalation (1.63 ± 0.05 vs. 2.39 ± 0.70 in
controls; p < 0.05; Figure 5C) suggesting subtl changes to ultrastructure may be nduced by He in
the heart.
Membrane fluidity was measured by electron paramagnetic spin resonance and a specific spin
label. Membrane frac ions of whole-heart tissue and PFP from the 24 h time point were repared to
det rmine membrane fluidity. 5-DSA was u ed as a spin label, and membrane fluidity was measured
by the S-ord r parameter that is directly proportional to membran rigidity. EPR spectra show
no significant changes af er He administration. However, a t e d towards decreased rigidity was
observed in whol -heart tissue and a trend (p = 0.099) towards increase rigidity was measured in
PFP (Figure 5D), again suggesting sub l alterations in membrane ultrastructure by He as a pot ntial
mechanism leading to protection dependent on circulating factors.
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magnification  11,000  ×.  Caveolae  are  indicated  by  the  black  arrow.  EC:  endothelial  cell,  SL: 
sarcolemma. No ultrastructural differences  in  cardiomyocytes were observed.  (B) The number of 
caveolae in the sarcolemma of left ventricular myocytes are depicted as caveolae/μm for both time 
points,  no  significant  differences  were  observed.  All  groups  had  the  same  sample  size  (n  =  4 
animals/group,  n  =  22–33  images  acquired  per  animal).  (C) Histogram  shows  the  results  of  the 
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of  baseline  metabolism  in  L6  muscle  cells  (Figure  6A,B).  Given  this  change  in  mitochondrial 
respiration, we  subsequently  assessed  the  impact of  serum on mitochondrial  function on mouse 
ventricular  tissue  using  the Oroboros O2k‐Respirometer. Helium‐conditioned  serum  resulted  in 
increased mitochondrial respiration through complex I and II, maximum oxidative phosphorylation 
capacity, and maximum uncoupled capacity in isolated myocardial fibers in the presence of complex 
I  substrates,  glutamate  and maleate  (Figure  6C).  To  determine  if  this  increased  respiration was 




Figure 5. ssess ent of cardiac ultrastructure and seru e brane fluidity post heliu exposure.
(A) Representative TE i ages fro left ventricular e branes of heart cells displayed per group,
agnification 11,000 ×. Caveolae are indicated by the black arrow. EC: endothelial cell, SL: sarcolemma.
No ultrastructural differences in cardiomyocytes were observed. (B) The number of caveolae in the
sarcolemma of left ventricular myocytes are depicted as caveolae/µm for both time points, no significant
differences were observed. All groups had the same sample size (n = 4 animals/group, n = 22–33
images acquired per animal). (C) Histogram shows the results of the cholesterol assay of whole-heart
tissue in µM/mL. Twenty-four hours after helium exposure significantly less cholesterol was left in
whole-heart tissue, n = 6 (control), n = 8 (helium). (D) The EPR histogram shows the changes in the S
order parameter 24 h after He inhalation in membrane fractions and PFP, n = 4. The S order parameter
is directly proportional to the membrane rigidity. No significant changes were observed. However, a
trend towards decreased rigidity in the He group and increased rigidity in PFP can be appreciated
when evaluating dedicated histograms. Data are shown as mean ± SD.
2.5. Biological Effect of Helium-Conditioned Serum on Mitochondrial Function
To determine if secreted factors in serum from helium-exposed mice have an impact on biological
function, we specifically assessed the impact of serum on regulating mitochondrial function as
mitochondrial function is critical in cardiac protection. We first assessed the impact of serum on
the ability to alter mitochondrial metabolism of L6 muscle cells in culture using Seahorse metabolic
flux assay. Addition of serum from helium-exposed mice resulted in a significant elevation of
baseline metabolism in L6 muscle cells (Figure 6A,B). Given this change in mitochondrial respiration,
we subsequently assessed the impact of serum on mitochondrial function on mouse ventricular tissue
using the Oroboros O2k-Respirometer. Helium-conditioned serum resulted in increased mitochondrial
respiration through complex I and II, maximum oxidative phosphorylation capacity, and maximum
uncoupled capacity in isolated myocardial fibers in the presence of complex I substrates, glutamate
and maleate (Figure 6C). To determine if this increased respiration was coupled and functional,
we next assessed the impact of serum from control and helium-exposed animals on superoxide
formation using electron paramagnetic resonance on isolated mouse cardiac mitochondria. We did not
observe any significant difference in superoxide formation between control and helium-conditioned
serum under state 3 or 4 conditions with complex I substrates (Figure 6D). These data suggest that
helium-conditioned serum is able to functionally increase mitochondrial respiration.
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consumption  rate  (OCR) was measured before and after  the addition of  inhibitors  (oligomycin, a 
complex  V  inhibitor;  FCCP,  a  protonophore;  and  antimycin A  and  rotenone,  complex  III  and  I 
inhibitors,  respectively)  to  derive  parameters  of mitochondrial  respiration.  (B) After  addition  of 
serum mean OCR was  calculated  after  normalizing  for  baseline OCR  of  the  L6  cells.  (C) High‐
resolution respirometry analysis was performed using the Oroboros O2k‐Respirometer. Serum from 
control  and  helium‐exposed  animals  was  incubated  with  naïve  mouse  heart  ventricular  tissue. 
Respiratory  function  of  complex  I  and  II  activity  (CI, CII), maximum  oxidative  phosphorylation 
capacity  (mOX) and maximum uncoupled capacity  (mUC) are  shown after addition of complex  I 
substrates glutamate and malate. (D) Electron paramagnetic resonance (EPR) with a DEPMPO spin 
probe was used  to assess  superoxide  formation  in  isolated mouse heart mitochondria exposed  to 




early  and  late  after He  exposure  (see  supplementary metabolomics  analysis  report, Tables  S2–5, 
Figures S1 and S2). Next, we specifically assessed circulating lipid metabolites in He‐treated versus 
the  control  group  using  liquid  and  gas  chromatography.  Evaluation  of  untargeted metabolomic 
profiling of He versus control group serum identified 174 known lipid metabolites (Table S2). The 
metabolites  failed  the  FDR  analysis  with  a  lowest  FDR  value  of  0.8,  indicating  no  significant 
differences between  the  lipid metabolites of  the control group and  the helium group. There were 





Figure 6. Biological effects of helium-conditioned serum on mitochondrial function. All assays utilized
serum collected 24 h post exposure. (A) L6 muscle cells were treated with serum (5%) from control or
helium-exposed mice. Seahorse Bioscience mitochondrial stress was assessed. Oxygen consumption
rate (OCR) was measured before and after the addition of inhibitors (oligomycin, a complex V inhibitor;
FCCP, a protonophore; and antimycin A and rotenone, complex III and I inhibitors, respectively) to
derive parameters of mitochondrial respiration. (B) After addition of serum mean OCR was calculated
after normalizing for baseline OCR of the L6 cells. (C) High-resolution respirometry analysis was
performed using the Oroboros O2k-Respirometer. Serum from control and helium-exposed animals
was incubated with naïve mouse heart ventricular tissue. Respiratory function of complex I and II
activity (CI, CII), maximum oxidative phosphorylation capacity (mOX) and maximum uncoupled
capacity (mUC) are shown after addition of complex I substrates glutamate and malate. (D) Electron
paramagnetic resonance (EPR) with a DEPMPO spin probe was used to assess superoxide formation in
isolated mouse heart mitochondria exposed to serum from control and helium-exposed animals under
state 3 and 4 conditions with complex I substrates. All assays utilized n = 4–6 samples/group.
2.6. Prim ry and Complex L pi Metabolites in Se um
No differences were observed in primary metabolites after correcting for false discovery rates
early and late after He exposure (see supplementary metabolomics analysis report, Tables S2–S5,
Figures S1 and S2). N xt, we specifically assessed circulating lipid metabolites in He-treated versus the
control group using liquid and gas chromatography. Evalu ti n of untargeted metabolomic profiling
of He versus control group serum identified 174 known lipid metabolites (Table S2). The metabolites
failed the FDR analysis with a lowest FDR value f 0.8, indicating n significant differences between
the lipid metabolite of the control gro p and the helium group. There were principal component
an lysis similarities between the He and control groups. The partial least squares discriminant analysis
(PLS-DA), which is a multivariate verfit model, also showed overlap b tween the He and control
grou s (Figure 7A). A heat map b sed on the normalized data a d p values showed more green
compared to red i the control group, indicating a lower abundanc of some metabolites in the helium
group compared with the control group (Figure 7B). Si ilarly, a list of metabolites positively and
negatively correlated with the He and control groups is listed in Figure 7C. Removing the outliers
as determined by the M taboanalyst (Quebec, QC, Canada) outlier algorithm showed the cer mide
group to be differentially regulated in He versus the control group (Figure 7D,E). The sphingolipid
Int. J. Mol. Sci. 2019, 20, 2640 8 of 18
metabolic pathway is associated with ceramide, and may be important to lipid raft/caveolae regulation.
This is represented by pathway annotation (Figure 7F).
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to  a  translocation  of Cav‐3  in  a  time‐dependent manner  after He  exposure. Changes  in mRNA 
expression profiles after He post  conditioning have been proposed  to be one of  the mechanisms 
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tissue. Cav‐1  is known  to be expressed  in many cell  types, whereas Cav‐3  is primarily present  in 
striated muscle cells. Cav‐1 has been linked to the signaling of ischemia–reperfusion damage, and 
Cav‐3 is found to be critical for cardiac function [28]. With subfractionation of the whole heart, we 
Figure 7. Complex lipid metabolites in serum. (A) Partial least squares discriminant analysis (PLS-DA)
between He and control groups. (B) Heat map based on the normalized data and p values. (C) List of
metabolites positively and negatively correlated with the He and control groups. (D,E) Removing the
outliers determined by the Metaboanalyst outlier algorithm show the ceramide group to be differentially
regulated in the He versus the control group. (F) Sphingolipid metabolic pathway associated with
ceramide identified using pathway annotation.
3. Discussion
Helium has been shown to protect several organs in healthy and diseased models [1,2,29,30].
Previous in vivo studies already showed that three 5-min inhalations of 70% He and 30% oxygen
prior to 30 min occlusion of the coronary artery and 3 h of reperfusion reduced cardiac infarct size in
rabbits significantly [27]. Helium-induced cardioprotection was also observed in a rat in vivo study [4].
A recent study showed that seven days after combined He pre/post conditioning, Cav-3 levels in
the rat heart decreased after an initial increase in a rat heart resuscitation model [24]. This might
point to a translocation of Cav-3 in a time-dependent manner after He exposure. Changes in mRNA
expression profiles after He post conditioning have been proposed to be one of the mechanisms
underlying He-induced cardiac protection in ischemic models [25,31]. Proteins of the reperfusion
injury salvage kinase (RISK) pathway have been implicated in He conditioning [25]. In the latter study,
caveolin levels were also investigated in a He post conditioning ischemia–reperfusion model in a rat.
Flick et al. showed that Cav-1 and Cav-3 levels increase after 15 min of helium post conditioning in the
membrane fraction of myocardial tissue [25]. To our knowledge, this is the first study to suggest that
helium-induced protection results in the release of circulating factors that are enriched in caveolins
and are necessary to produce the protective phenotype. This is observed as a loss of this effect in the
isolated heart preparation and the ability of the conditioned serum from helium-exposed animals to
impact mitochondrial function in a number of preparations.
3.1. Circulating Factors
In our study, we show that Cav-1 and Cav-3 levels are downregulated after 24 h in whole-heart
tissue. Cav-1 is kno n to be expressed in many cell typ s, whereas Cav-3 is primarily present in striated
muscle cells. Cav-1 has been linked to the signaling of ischemia–r perfusion damage, and Cav-3 is
found to be critical for c rdiac function [28]. With subfractionation of the whole heart, we determine
th t this l ss was specific to the membra e fractions, with no change seen in cytosolic fractions.
Corresponding to the decreased Cav-1 and Cav-3 levels in whole-heart tissue and in membrane
fractions, we observed increased levels of Cav-3 in PFP and also of Cav-1, though not significant.
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Correlating with this, levels of cholesterol decreased in the membrane fractions 24 h after exposure,
suggesting a secretion of caveolins and lipids from cardiac cell membranes into the blood stream.
These findings are completely in line with our previous findings employing human endothelial cells
to investigate the direct effects of He in vitro [26]. We showed that He in fact induces the release of
caveolin to the supernatant of endothelial cells, and that the supernatant can preserve endothelial
dysfunction by maintaining endothelial permeability [26]. Importantly, when we performed isolated
heart studies in the present investigation, we demonstrated that the He-induced protection seen in the
in vivo setting was no longer observed. Taken together these data, this strongly suggests that the loss
of circulating factors may lead to a loss of protection in an isolated heart system.
We used EPR to determine changes in membrane fluidity possibly caused by changes in structural
membrane proteins. Our data show a trend towards decreased rigidity in whole-heart tissue from
helium-treated mice 24 h after He inhalation, and a trend towards increased rigidity in PFP in the
same group and time point. As caveolins are rigid structural membrane proteins, the trend towards a
decrease of rigidity in He-treated whole-heart tissue, and the trend towards increased rigidity in PFP,
support our hypothesis of secreted caveolins and lipids from tissue into the bloodstream.
So far it has been challenging to find an agent that can effectively increase levels of caveolin to
confer an organ-protective effect. Different models have already been used, such as directly targeting
Cav-3 signaling with a Cav-3 scaffolding domain peptide or Cav-3 overexpression by an adenovirus,
both which have led to cardioprotective effects [11,32]. Despite successful use of these techniques in
preclinical models, such therapies may be difficult to translate into humans.
3.2. Remote Protection
As caveolins play a critical role in regulating cardiac-protective signals in plasma membrane,
circulating caveolins could also interact with distant membrane proteins to yield cardiac protection.
In the present study, we failed to show protection in the isolated perfused Langendorff heart after
He inhalation, suggesting that the circulating component of He conditioning is critical to protection.
In contrast, other groups have shown that injection of remote-conditioned serum from healthy volunteers
induces protection ex vivo in the model of Langendorff [33,34]. Several mediators and targets involved
in remote cardiac protection have been identified recently. Most prominently, cardioprotective factor
X, microRNA, nitric oxide and exosomes have been discussed [35]. Interestingly, microvesicles and
exosomes produced by different cell types via exocytosis contain apoptotic caspase 3, and may function
as warning messengers for nearby cells in instances of reduced membrane integrity [36]. Moreover,
the larger extracellular vesicles and endothelial-derived exosomes contain Cav-1, and the inhibition of
caveolin-enriched microdomains blocks the release of exosomes [37]. Thus, caveolins could be the
key component facilitating exosome secretion containing protective factors. We show that the serum
from helium-conditioned mice has a biological benefit to enhance mitochondrial respiration without
any significant increase in reactive oxygen species generation. Therefore, caveolins and the protective
factors associated with caveolin in secreted particles may be essential to mediating remote protection.
Circulating caveolins could be of importance beyond the field of cardioprotection. Potential
anticancer therapy, as chemotherapy shows increased levels of Cav-1 in cancer cells after
chemotherapeutic exposure [38]. Most importantly, in certain cancer types it has been shown that
caveolin secreted by prostate cancer cells might stimulate cell survival and angiogenic activities [39–42].
These studies thereby suggest a role for secreted caveolin as a mediator of cell survival [41]. Elevation
or knockdown of Cav-1 expression plays a critical role in chemosensitivity [43]. Because Cav-1 is
upregulated during cell stress, it has been proposed that Cav-1 is a stress-related molecule that can
be upregulated by various mechanisms [44]. It is also possible that Cav-1 may induce such effects
by regulating interaction with other cell proteins (e.g., calpain) to modulate the stress responses that
control cellular process, such as autophagy and mitochondrial protection, which may be critical to
acute adaptation from ischemia–reperfusion injury [45].
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As circulating factors other than caveolins are proposed to play a role in cardiac conditioning in
blood [33], consideration of other protective mediators is also necessary. Therefore, we also analyzed
primary metabolites and complex lipid metabolites from He-conditioned serum to identify potential
changes in metabolic patterns. We did not observe any significant changes in early (30 min) or late
(24 h) primary metabolites post He exposure, suggesting the likelihood that other blood components
(i.e., exosomes, bioactive lipids, proteins, etc.) that we did not analyze could be the missing factors for
the observed protective effects of He. The altered EPR signal in the PFP samples (which are enriched in
microparticles, exosomes, etc.) suggest altered lipid content, and future studies should focus on the
biological function of cell-derived membranes in these compartments.
Ceramide synthases play a critical role in sphingolipid metabolism and the formation of endocytic
vesicles. The gene responsible for the expression of ceramide synthases is the longevity assurance
gene (LAG1), identified in a yeast-aging model. Deletion of the LAG1 gene results in the extension
of lifespan in yeast [46]. Ceramides added to ATP-depleted macrophages result in the formation of
endocytic vesicles that are not caveolin positive [47]. When caveolins are synthesized in the endocytic
vesicles, they form caveolae. Overall, He induction increases caveolae formation, and the release may
involve ceramides and the sphingolipid metabolism. How caveolins are added to the endocytic vesicle
and transported outside cells into the blood stream needs further investigation.
In the present study, we aimed to contribute to the understanding of the mechanism behind
He-induced cardiac protection. One major limitation in this study was that the animals used were
relatively young and healthy. If the proposed mechanism is to be translated to patients suffering
from heart disease or at risk of heart disease, similar conditions should be mimicked in the animal
experiment. As our findings are limited to one species of healthy mice, further confirmation of our
findings should be explored in cells and aged animal models. Additionally, we used Na+/K+ATPase as
a housekeeping protein and normalized Cav-1 and Cav-3 to this. It is possible that longer time points
post helium exposure have more profound effects on membrane ultrastructure impacting normalization
controls. This is an area that has not been well investigated in the literature and may warrant focus in
future studies.
4. Materials and Methods
4.1. Animal Handling
All animal experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) at the VA San Diego Healthcare System. Animals were treated in accordance with the Guide
for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996). Furthermore,
all experiments where performed according to the ARRIVE guidelines. C57BL/6J mice were purchased
from Jackson Laboratory (Bar Harbor, ME, USA) at eight weeks of age, and all experiments were
performed in young male mice between 8–12 weeks of age. Animals were kept on a 12-h light/dark
cycle in a temperature- and humidity-controlled room with ad libitum access to food and water.
4.2. General Chemicals and Solutions
If not otherwise stated, all chemicals and solutions were purchased from Sigma-Aldrich Corp.
(St. Louis, MO, USA), Santa Cruz Biotechnology (Dallas, Texas, USA), BD Bioscience (San Jose, CA,
USA) or Millipore (Massachusetts, MA, USA).
4.3. Anesthesia Exposure Protocol and Tissue Collection
Animals were exposed in a standard cage plexiglass chamber (#7060R, Columbus Instruments,
OH, USA) for 30 min at a flow of 5 L/min to either a treatment of 70% He/30% oxygen mix, or a
concentration of 30% oxygen in air as a control group. After 30 min or 24 h, blood was collected
through cardiac puncture and hearts were excised under deep pentobarbital (50 mg/kg i.p.) anaesthesia,
flash frozen in liquid nitrogen and stored at –80 ◦C until further processing (Figure 8).
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Figure 8. Experimental protocol overview of organ and bl od c llection. C57BL/6J mice were
randomized into two different groups. Subsequently, mice inhaled either 70% He r 30% oxygen for
30 mi in a Plexiglas chamber. Thirty minutes or 24 h post exposure, blood was drawn and hearts were
excised for further analysis. PFP: platelet free las a, : st exposure.
4.4. La gendorff Perfused Heart Model
Twenty-four h after He or Ctrl exposur , mice were an sthe ized with sodium pentobarbital
(50 mg/kg i.p.), the heart excised and the aorta cannulated for Langendorff perfusion of the coronary
irculation, as described previously [48,49]. All hearts were perfused at a hyd o tatic pressure of
80 mmHg with modified Krebs–Henseleit ffer bubbled with 95 O2/5% CO2 at 37 ◦C, containing:
119 mM NaCl, 22 mM NaHCO3, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 1.2 KH2PO4,
11 mM D-glucose and 0.5 mM EDTA. For the ischemia–reperfusion (I-R) protocol, a 20-min normoxic
stabilization at intrinsic heart rates was followed by ventricular pacing at 7 Hz. After an additional
10 min, baseline measurements were made before subjecting hearts to 25 min of global, normothermic
ischemia, followed by 45 min aerobic reperfusion with pacing re-introduced after 2 min.
4.5. Immunoblot Analysis
Immunoblot analyses were performed as previously described [50]. Flash-frozen tissue was
homogenized on dry ice using a metallic potter. After re-suspending the tissue powder in lysis buffer
containing 10 mM Hepes, 2 mM EDTA and 1 mM MgCl2, the solution was passed through a 21-gauge
needle and subsequently sonicated at 30% amplitude on ice three times for 10 s. Protein concentration
was determined by Bradford analysis (BioRad; Hercules, CA, USA) using spectrophotometry at a
wavelength of 595 nm on an Infinite M200 plate reader (Tecan; San Jose, CA, USA). Protein was
separated on a 10%–12% polyacrylamide precast gel. Proteins were transferred to a polyvinylidene
difluoride membrane by electroblotting. Membranes were blocked in tris-buffered saline with 1% tween
(TBST) containing 3% bovine serum albumin (BSA) solution. Afterwards, the me brane was incubated
with the respective primary antibody in 3% BSA (1: 000, mouse antibody anti-Cav-3, mouse anti-Cav-1
and rabb t anti-GAPDH 1:5000) at 4 ◦C overnight. Primary antibodies were visual zed using secondary
antibodies (1:5000 in TBST) conjugated wit horseradish peroxidase from Santa Cruz B otechnology.
The enhanced chemiluminescent r agent from Amersham Bi sciences (Piscataway, NJ, USA) was
used for the detection of protein bands. In comparison t a molecular w ight standard (Sa ta Cruz
Biotechnology, Dallas, TX, USA), the appropriate sizes of the bands were proven.
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4.6. Cholesterol Assay
The cholesterol assay of whole-heart tissue was performed using the Amplex Red Cholesterol assay
kit from Invitrogen (Carlsbad, CA, USA) according to the manufacturer’s instructions. After 60 min
incubation (37 ◦C, in the dark), fluorescence was measured. Cholesterol levels were determined from
cholesterol standard curves.
4.7. Quantitative Real-Time Polymerase Chain Reaction (RT-PCR)
About 30 mg of heart tissue was flash frozen in liquid nitrogen then pulverized with a cold mortar.
From the 24-h time point, hearts were used for the RT-PCR analysis. Subsequently, the powder was
homogenized in Tripure isolation reagent (Roche, the Netherlands). Total RNA was extracted from
100 µl homogenate using the NucleoSpin RNA Midi kit (Macherey-Nagel, The Netherlands) according
to the manufacturer’s protocol. Next, RNA concentration was determined by UV-Vis absorbance
spectroscopy NanoDrop 2000 (Thermo Scientific, Rockford, IL, USA). According to manufacturer’s
instructions, 300 ng of RNA was reverse transcribed to cDNA using the Transcriptor First Strand cDNA
Synthesis Kit, and 1 µl cDNA was used in a total volume of 10 µL PCR mix per reaction. Each mixture
contained 10 µM of primer pairs (Table S1) and 2× LightCycler 480 SYBR Green I Master (Roche).
Real-time qPCR amplification was carried out using the LightCycler 480 instrument (Roche) under the
following conditions: pre-incubation at 95 ◦C for 10 min, followed by 42 cycles of 95 ◦C for 15 s, 56 ◦C
for 10 s and 72 ◦C for 15 s.
Analysis of raw data was conducted using the programs LC480Converter and LinRegPCR.
For each sample, PCR efficiency was determined. Subsequently the means of the PCR efficiencies per
target were used to calculate the estimated starting concentration per sample. Afterwards, each target
gene was normalized to the housekeeping gene GAPDH [51].
4.8. Isolation of Membrane and Cytosolic Fractions
Flash-frozen tissue was homogenized as described in Section 4.5. After sonication, the suspension
was centrifuged at low speed (500 g) for 10 min at 4 ◦C to pellet cell debris. The supernatant was
centrifuged in an Optima Max tabletop ultracentrifuge (Beckmann Coulter Inc., Brea, CA, USA,
swinging rotor TLS 55) for 30 min at 37,000 g. The resulting pellet was re-suspended in hypotonic lysis
buffer and used as the particulate fraction for immunoblotting and EPR. The supernatant was again
centrifuged at the same speed for 30 min and the resulting supernatant was used as cytosolic fraction
for immunoblotting.
4.9. Isolation of Serum, Platelet Free Plasma and Exosomes
Serum was collected as described in Section 4.3 and subsequently isolated to clot at room
temperature for 30 min in Becton Dickinson serum collection tubes. After this, blood was centrifuged
at 1200 g for 15 min at room temperature. The supernatant was used as serum.
PFP blood was collected in citrate buffer and centrifuged at 1200 g for 15 min at room temperature.
The supernatant was collected, and a further centrifugation step was performed at 12,000 g for
12 min. The supernatant, platelet free plasma (PFP), was further analyzed using electron paramagnetic
resonance spectrometry. Furthermore, exosomes were isolated from PFP. PFP was centrifuged at
20,000 g at 4 ◦C for 40 min in the ultra mini centrifuge (Optima Max tabletop centrifuge TLA 55 rotor
SN12/1150) using no brake.
The supernatant was again centrifuged at 100,000 g at 4 ◦C with no brake for 95 min.
The pellet containing exosomes was directly suspended in high pH buffer (150 mM Na2CO3
and 1 mM Na EDTA). Each sample was than sonicated on ice for 3 × 15 s at 30% power and further
processed for standard western procedure.
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4.10. Electron Paramagnetic Resonance Spectrometry (EPR)
As previously described, hydrocarbon chain mobility was measured using fatty acid spin labelling
EPR analysis with 5-DOXYL-stearic acid (5-DSA) as a spin probe [52–54]. The number designation
indicates the relative position of the nitroxide on the stearic acid relative to the polar carboxylic group.
5-DSA probes membrane rigidity close to the hydrophilic surface of the membrane [55]. Platelet free
plasma or crude membrane extracts of the heart tissue were incubated for 10 min with a specific spin
label (1 mM final concentration) at room temperature (25 ◦C). The mixture was then loaded into a 50-µL
glass capillary tube and inserted into the EPR cavity of a MiniScope MS300 Benchtop spectrometer
(Magnettech, Berlin, Germany). The MiniScope was maintained at 25 ◦C, and the EPR spectra were
measured. EPR conditions were the following: microwave power, 5 mW; modulation amplitude, 2 G;
modulation frequency, 100 kHz; sweep width, 150 G centred at 3349.0 G; scan rate, 7.5 G/s, with each
spectrum representing the average of 20 scans. The fluidity parameters T‖ and T⊥ were used to
calculate the order parameter as previously described [54,55].
For superoxide measurement studies, mitochondria were isolated as previously published [10].
Isolated mitochondria (0.1–0.2 mg of protein) were incubated with the control or helium serum (5%) for
5 min, then with 70 mM 5-(diisopropoxyphosphoryl)-5-ethyl-1-pyrroline-N-oxide (DEPMPO, 5 min).
After addition of the appropriate combinations of substrates, the mixture was loaded into 500-µl glass
capillary tubes and introduced into the EPR cavity of a MiniScope MS300 benchtop spectrometer
(Magnettech GmbH, Berlin, Germany). We confirmed that the detected EPR signals were substrate
specific, and not due to redox cycling in the studied mixtures, by noting a lack of signals when
DEPMPO was mixed with combinations of substrates and inhibitors in the absence of mitochondria.
Assignment of the observed signals from mitochondria was confirmed through computer-assisted
spectral simulation using the WinSim software (http://epr.niehs.nih.gov/pest.html). Validation of the
signal was performed as previously described [10]. Signals were quantified by measuring the peak
amplitudes of the observed spectra.
4.11. Transmission Electron Microscopy (TEM)
Cardiac tissue was assessed via TEM in four hearts of each group, with specific emphasis on
the quantification of caveolae on the sarcolemma and mitochondrial morphology. Animals were
anesthetized with pentobarbital (50 mg/kg i.p.) and transcardial perfusions (5 mL/min) were performed
in deeply anesthetized animals initially with 37 ◦C perfusion buffer (3 min, Ca2+ and Mg2+ free
DPBS, 10 mM HEPES, 0.2 mM EGTA, 0.2% BSA, 5 mM glucose and 9.46 mM KCl), followed by 37 ◦C
fixative (3 min freshly prepared 2.5% glutaraldehyde, 2% paraformaldehyde in 0.15 M cacodylate
buffer) using a peristaltic pump (Langer Instruments, Boonton, NJ, USA) as described previously [56].
The left ventricular free wall was dissected immediately, and small tissue pieces were immersed in
fixative for 2 h at room temperature, followed by overnight incubation in fixative at 4 ◦C. Samples
were post-fixed in 1% OsO4 in 0.1 M cacodylate buffer, enbloc stained with uranyl acetate (2%−3%),
dehydrated in ethanol, embedded in longitudinal orientation in Durcupan epoxy resin (Sigma-Aldrich)
and polymerized for 48 h at 60◦. Blocks were sectioned at 50–60 nm on a Leica UCT ultramicrotome
(Wetzlar, Germany), picked up on Formvar and carbon-coated copper grids and stained in uranyl
acetate and lead citrate prior to TEM photography (Jeol 1200 EX-II; Jeol Ltd., Akishima, Japan). Blinded
observers acquired scans of four capillaries with surrounding sarcolemma per animal (n = 4 hearts per
group, total capillaries n = 24) at 1900×, 2900× and 11000× magnifications using a Tecnai G2 Spirit
BioTWIN (FEI, Hillsboro, OR, USA) transmission electron microscope. Images were captured using an
Eagle 4k HS digital camera (FEI). The total density of caveolae/100 µm cardiomyocyte sarcolemma was
quantified using ImageJ (National Institutes of Health, Bethesda, MD, USA).
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4.12. Seahorse Mitochondrial Respiration Assay
The ability of serum to alter cellular metabolism was performed as previously published [57].
Briefly, oxygen consumption rates (OCR) from a monolayer of adherent L6 muscle cells purchased from
ATCC Cat. # CRL-1458), were measured using a Seahorse XF96 analyzer. The L6 cells were seeded at
20,000 cells/well (passage 3−4) on a 96-well tissue culture plate (Seahorse Biosciences, North Billerica,
MA, USA) 24 h before the OCR measurements. The bioenergetic profile was derived by acutely
injecting control or helium serum (5%) through the first of the four injection ports, followed by the
modulators of the electron transport chain. The OCR was calculated by plotting the O2 tension of the
media as a function of time (pmol/min).
4.13. High-Resolution Mitochondrial Respirometry
Mitochondrial function in manually dissected fibers from the left ventricular free wall of mouse
hearts were evaluated using an Oroboros O2k-Respirometer. Heart samples weighed between
0.5 and 1.0 mg. Serum (5%) from the control and helium-exposed animals was incubated in the
oximetry chamber along with ventricular tissue in media containing: 100 mM KCl, 75 mM mannitol,
25 mM sucrose, 5 mM H3PO4, 0.05 mM EDTA and 10 mM Tris HCl; pH 7.2, at 37 ◦C. After 10
min of equilibration, respiratory function of complex I and II activity (CI, CII), maximum oxidative
phosphorylation capacity (mOX) and maximum uncoupled capacity (mUC) were determined after
addition of complex I substrates, glutamate and malate. Oxygen use trace and rate determinations
were obtained using DatLab 7 software and normalized to protein.
4.14. Metabolomics
Serum metabolomic analysis was performed by the West Coast Metabolomics Center, UC Davis
Genome Center, University of California Davis, 451 Health Sciences Drive, Davis, California 95616,
United States. An unbiased assessment of primary and complex lipid metabolites were identified in
serum as per center protocols. Data were subsequently analyzed with MetaboAnalyst software 3.0.
4.15. Statistical Analysis
All data are Mean± SD. Statistical analysis was performed in GraphPad Prism (GraphPad Software
version 5.01, La Jolla, CA, USA) using one-way ANOVA and two-way ANOVA with Bonferroni post
hoc tests for multiple comparisons. Data were tested for normality distribution using D’Agostino
and Pearson normality testing. Normally distributed data of two groups were compared using an
unpaired t-test (with Welch’s correction) and not normally distributed data were compared using a
Mann–Whitney test. p < 0.05 was considered significant.
5. Conclusions
The data of the present study show that after He inhalation, Cav-1 and -3 circulate in the blood,
and that no cardiac protection could be achieved in isolated hearts without these circulating blood
components. The current data add mechanistic insight to recently published data showing that He can
affect caveolin release in human cells. The current work suggests a critical role for circulating factors in
He-induced organ protection.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/11/
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